Dual Targeting of the HER2 Receptor
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.
Clinical Pearls
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.
- Dual targeting of the HER2 receptor proved to better than single targeting, resulting in an improvement in pathological complete remission
- Presence of a pathological complete remission correlated with increased disease-free survival and overall survival in patients with hormone receptor-positive and hormone receptor-negative disease
Recent Videos
Related Content
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024Article
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
